Medical artificial intelligence (AI) corporations Lunit said on the 30th that it posted 83.1 billion won in revenue last year on a consolidation basis. That was up 53% from the previous year's 54.2 billion won, marking a new annual record.
Overseas revenue was 76.8 billion won, accounting for 92% of the total. It rose 61% from the previous year's 47.8 billion won. Fourth-quarter revenue was 26.5 billion won, up 32% from 20 billion won a year earlier.
Operating loss was 83.1 billion won, with the loss-to-revenue ratio improving 25 percentage points, to 1.0 times from 1.25 times a year earlier. Lunit emphasized that in 2024 only eight months of Lunit International's (formerly Volpara) operating expense were reflected, but last year all annual expenses were included while the loss ratio declined, indicating improved operational efficiency. It added that in December of last year it also generated positive monthly EBITDA, showing visible progress in profitability.
It cited the AI biomarker platform "Lunit Scope" as the key driver of revenue growth. Revenue in the oncology business increased 159% from the previous year to surpass 10 billion won, and the cancer diagnosis sector also maintained steady growth centered on hospitals and screening markets.
Chief Executive Seo Bum-seok said, "The AI biomarker business centered on Lunit Scope has entered full-fledged monetization," and noted, "Cooperation with global leaders in each field, such as Daiichi Sankyo and Agilent, has led to concrete results." He added, "By bolstering capital, we will resolve uncertainty related to the convertible bond put option, and this year we will achieve revenue expansion and improved profitability on a stable financial base."
Lunit plans to expand its global partnerships and regions for commercialization this year.